Callisto Pharmaceuticals Redirects Atiprimod Clinical Development To Treat Rheumatoid Arthritis

Podiatry Arena Callisto Pharmaceuticals Redirects Atiprimod Clinical Development To Treat Rheumatoid Arthritis

Welcome to the Podiatry Arena forums, for communication between foot health professionals about podiatry and related topics.

You are currently viewing our podiatry forum as a guest which gives you limited access to view all podiatry discussions and access our other features. By joining our free global community of Podiatrists and other interested foot health care professionals you will have access to post podiatry topics (answer and ask questions), communicate privately with other members (PM), upload content, view attachments, receive a weekly email update of new discussions, earn CPD points and access many other special features. Registered users do not get displayed the advertisments in posted messages. Registration is fast, simple and absolutely free so please, join our global Podiatry community today!

If you have any problems with the registration process or your account login, please contact contact us.

Callisto Pharmaceuticals Redirects Atiprimod Clinical Development To Treat Rheumatoid Arthritis

Submit Thread >

< Submit Thread

Thread Tools

Display Modes

29th January 2009, 05:40 AM

RSSFeedBot RSSFeedBot is offline

I, Robot

About:

Join Date: Jul 2008

Posts: 3,062

Join Date: Jul 2008

Marketplace reputation 0% (0)

CPD Points: 1

Thanks: 0

Thanked 5 Times in 5 Posts

Callisto Pharmaceuticals Redirects Atiprimod Clinical Development To Treat Rheumatoid Arthritis

Podiatry Arena members do not see these ads

Callisto Pharmaceuticals, Inc. (OTC BB: CLSP.OB) today announced that it is focusing further development of atiprimod on treatment of rheumatoid arthritis (RA). Atiprimod has demonstrated a favorable clinical safety profile robustly supported by earlier RA studies as well as by recent oncology trials in advanced carcinoid cancer patients, where the drug was dosed at levels and frequencies considerably higher than anticipated for use in RA.

More...

Sponsored Links

« Previous Thread | Next Thread »

Thread Tools
Show Printable Version Email this Page
Display Modes
Linear Mode Switch to Hybrid Mode Switch to Threaded Mode

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts	vB code is On Smilies are On [IMG] code is On HTML code is On

Forum Jump

Translate This Page

Similar Threads

Thread	Thread Starter	Forum	Replies	Last Post
Key US Patent Granted On Antibodies Against GM-CSF To Treat Inflammatory Disorders (Rheumatoid Arthritis)	RSSFeedBot	Latest Rheumatology News	0	25th November 2008 09:10 AM
Rheumatoid Arthritis - Cimzia(R) Studies Show Significant Clinical Benefits For Mono- And Combination Therapy	RSSFeedBot	Latest Rheumatology News	0	18th November 2008 07:31 AM
University Of Kentucky Launches Clinical Outcomes-Based Educational Initiative To Reinforce Rheumatoid Arthritis (RA) Standards Of Care	RSSFeedBot	Latest Rheumatology News	0	28th October 2008 12:10 PM
Development of pes planovalgus in rheumatoid arthritis	Admin	General Issues and Discussion Forum	0	6th February 2005 01:21 PM

New To Site?	Need Help?
Register to Participate View Forum Leaders Contact Us	Frequently Asked Questions Did you forget your password? Mark Forums Read

Finding your way around:

Browse the forums.

Search the site.

Browse the tags.

Search the tags.

All times are GMT -7. The time now is 06:03 AM.

User Name		Remember Me?
Password